MRVI Q3 2021 Earnings — Maravai LifeSciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

MRVIMaravai LifeSciences Holdings, Inc.

$970M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$205M+133.1% YoY

Gross Profit

$173M84.3% margin

Operating Income

$155M75.9% margin

Net Income

$54M26.3% margin

EPS (Diluted)

$0.44

QoQ Revenue Growth

-6.0%

Cash Flow

Operating Cash Flow

$106M

Free Cash Flow

$104M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.9B

Total Liabilities

$1.4B

Stockholders' Equity

$303M

Cash & Equivalents

$548M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$205M	$88M	+133.1%
Gross Profit	$173M	$68M	+153.4%
Operating Income	$155M	$46M	+239.8%
Net Income	$54M	$39M	+38.5%

Revenue Segments

Nucleic Acid Production Segment

$183M89%

Biologics Safety Testing Segment

$17M8%

Protein Detection Segment

$5M3%